At least 11% and 6% of the targeting efficiency were achieved for transgene insertion and telomereassociated truncation, respectively. The transgene insertion was also confirmed in A9 cells (29%). The modified chromosomes were transferrable to other cells. Thus, this CHO and A9 cell-mediated chromosome engineering using the CRISPR/Cas9 for direct transfer of the modified chromosome is a rapid technique that will facilitate chromosome manipulation.
, pluripotent stem cells from patients with genetic disease for the genetic correction 7 and cancer cell lines to investigate cancer suppressor genes 3, 8, 9 . In addition, mammalian artificial chromosome vectors, including human artificial chromosome (HAC) 10 and mouse artificial chromosome (MAC) 11, 12 vectors into which megabase-sized chromosomal loci and multiple cDNAs can be loaded [13] [14] [15] [16] [17] , have been used with these techniques and cells. Such techniques are promising for various biomedical challenges. However, a modified chromosome in DT40 cells cannot be easily transferred into another cell type, except for into CHO-K1 cells. Therefore, the current technique requires three rounds of MMCT and repeated chromosomal analysis after each transfer (Fig. 1a) .
Genome editing techniques using artificial nucleases (ZFNs 18 , TALENs 19 , CRISPR/Cas9 20 ) have high HR efficiency of transgene insertion and deletion via targeted sequence-specific DNA breakage and DNA repair pathways in various host cells, even in fertilised eggs and somatic cells of various eukaryotic animals 21 . Recently, a CHO-K1 cell sub-strain, CHO-S, which is generally used for recombinant protein production, was modified with genome editing techniques [22] [23] [24] [25] . Here, we report a direct manipulation of a specific transgene insertion and telomere-associated truncation in a single human chromosome in CHO-K1 cells using CRISPR/Cas9. The transgene insertion were also performed in mouse A9 cells containing a human chromosome 8 (hChr.8) 26 . In addition, MMCT of the modified chromosome was achieved from the CHO-K1 cells to recipient cells (Fig. 1b) .
Results
Design of CRISPR/Cas9 and targeting plasmid vectors. Previously, we established CHO-K1 cells containing a human chromosome 21 (hChr.21) 10 . In this study, this hChr.21 was used for transgene insertion, telomere-associated truncation and transfer of the modified chromosome to other cells by MMCT.
The targeting plasmid and telomere-associated truncation plasmid vectors contained homologous recombination (HR) arms, located near the centromere, and a positive selection resistance gene against blasticidin S (Bsd) or L-histidinol dihydrochloride (hisD). A suicide gene, Fcy; Fur, for negative selection, [Fcy; Fur causes cytotoxicity by metabolising 5-flucytosine (5-FC)] was inserted into the targeting plasmid vectors to eliminate cells harbouring unexpected insertion/s of a targeting plasmid vector in a host CHO chromosome ( Fig. 2a and b) .
To induce transgene insertion and telomere-associated truncation by homologous recombination at targeted sites, we designed sgRNA expressing plasmid vectors based on pX330, which can co-express sgRNA and SpCas9
27
. AP000167 and AP001657 loci were targeted by CRISPR/Cas9. Two HR arms were randomly selected from the AP000167 locus. Candidate sgRNA sequences were selected from an approximately1kb region between the two HR arms using Optimized CRISPR design tool (http://crispr.mit.edu/) 27 . Similarly, the HR arm for telomere-associated truncation was randomly selected from the AP001657 locus. The candidate sgRNA sequences were selected from the region downstream of the selected HR arm. Six and four sgRNA-expressing pX330 vectors were designed for transgene insertion and telomere-associated truncation, respectively. These sgRNA-expressing vectors were then evaluated for their cleavage activity by Cel-I assays. The two vectors with the best cleavage activity were used for the subsequent experiments. These were AP000167T1 (cleavage activity: 17.2%) and T11(9.6%) for transgene insertion and AP001657T5 (7.4%) and T6 (9.4%) for telomere-associated truncation. Because, dual expression of two sgRNAs improves cleavage activity with the CRISPR/Cas9 system 28 , this chromosome modification in CHO-K1 cells has the advantage of reducing the possibility of CRISPR/Cas9 off-target activity. Generally, there is a possibility of off-target activity towards unexpected regions because of similar DNA sequences in other regions of the genome. This chromosome modification and transfer technique can target only one chromosome and even if the host chromosome was unexpectedly disrupted by CRISPR/Cas9, such off-target modifications of the host genome are excluded via MMCT. Therefore, choosing a specific sequence on one chromosome will reduce off-target events. Chromosomal transgene insertion and telomere-associated truncation using the CRISPR/Cas9 system in CHO-K1 cells. To insert the targeting vector into hChr.21, the CHO-K1 cells containing hChr. 21 were transfected with the two CRISPR/Cas9 vectors; AP000167T1 and T11 and the circular I-EGFP-I-Bsd-Fcy; Fur plasmid vector. The transfected cells were expanded for 5days and then treated with 8 µg/mL blasticidin S and 200 µM 5-FC (the substrate of Fcy; Fur) for 21 days. From the resulting colonies, 37 were randomly isolated, and genomic DNA was extracted. PCR analyses were performed with two primer pairs (primer pairs#1 and #2) (Fig. 2a ) and 17 clones (46%) showed the expected HR bands (Fig. 3a) (see Supplementary Fig. 1a ). Thirteen well growing clones were analysed by fluorescence in situ hybridisation (FISH), all the clones contained hChr.21 with various frequency (Table 1 and Fig. 3c) . Thus, at least 13 (35%) of 37 isolated clones showed the transgene insertion. CHO cells are chromosomally abnormal, and often unstable with aneuploidy and polyploidy. Thus, the variation of the copy number of modified chromosome and polyploidy were likely occurred after the modification. Although it is not excluded that CRISPR/Cas9 induces chromosome instability, there are no report on this event.
To truncate a telomere of hChr.21 in CHO-K1 cells, the CHO-K1 cells containing hChr.21 were transfected with two CRISPR/Cas9 vectors, AP001657T5 and T6, and with the linearised truncating vector, pBS-TEL/ Dq HisDv2-Fcy; Fur. The transfected cells were expanded for 5days and then treated with antibiotics (7 mM L-histidinol dihydrochrolid and 200 µM 5-FC). Forty-eight clones were isolated, and PCR analyses were , and a linearised pBS-TEL/Dq HisDv2 Fcy; Fur vector inserted, which contained a single homologous recombination arm, 1 kb of artificial telomere sequence and a histidinol dihydrochlorideresistant gene (hisD). Primer pair #3 was designed to detect correct homologous recombination and primer pairs #4, 5 and 6 were designed to detect deletion of chromosome regions. Ideally, primer pair #3 should produce a PCR amplicon and primer pairs #4, 5, and 6 should not produce any PCR amplicons. (Fig. 2b) to detect the expected homologous recombination with three primer pairs (primer pairs #4, 5 and 6), to verify that loci were deleted by telomere-associated truncation as expected.
The correct homologous recombination was detected in 10 of 48 (21%) clones. Among them, CHO HisD#44 was negative for all telomere-associated truncation loci ( Fig. 3b ) (see Supplementary Fig. 1b ). Among the 10 clones, which showed positive result with primer pair #3, a morphological change in the size of Chr.21 was observed in four clones (8%) (CHO HisD #04, 21, 36, 44) with more than 25% of 20 analysed cells. FITC signal indicating the presence of transgene was detected on the terminal of the truncated hChr.21 (Fig. 3d) . QH banding pattern showed the deletion of long arm of the truncated hChr.21 at q11 to terminal end (Fig. 3e) . These PCR and FISH results of telomere-associated truncation suggested that 9 clones except for HisD#44 were a mixture of the truncated and non-truncated cells. MMCT was performed with the four clones (CHO HisD #04, 21, 36, 44) to mouse B16F10 for confirmation of the occurrence of the expected telomere-associated truncation.
Transfer of the manipulated chromosomes from CHO-K1 cells to recipient cells by MMCT.
To be useful for further biomedical applications, it is essential that the modified chromosomes can undergo MMCT. Five (CHO Bsd #06, 22, 30, 32, 36) clones in which the I-EGFP-I-Bsd-Fcy; Fur vector was inserted, were transferred by MMCT into HT1080 cells as a model of human cancer cells. Thirty-two clones showed well growth and were analysed by PCR. Thirty-one of the 32 clones were positive for the modified hChr.21 by PCR analysis with primer pairs #1 and 2. A representative result is shown in Fig. 4a . For each group derived from each CHO-donor clone, seven PCR-positive-clones were randomly selected for FISH analysis. Six of the 7 clones showed the presence of the expected hChr.21 (Table 2 ) (see Supplementary Fig. 1a ), demonstrating HT1080 clones derived from CHO Bsd clones. Accordingly, 4 of 5 CHO donor clones (CHO Bsd #06, 22, 30, 32) could transfer the expected modified hChr.21. Thus, at least 4 (11%) of 37 isolated CHO clones were confirmed to have the transgene insertion.
Four (CHO HisD #04, 21, 36, 44) representative CHO clones containing the truncated human chromosome were used as donor cells to transfer the truncated chromosome to B16F10, because the human chromosome can be distinguished from mouse chromosome. Thus, the truncation can be confirmed. The cells, which were performed MMCT were selected with hisD. Each MMCT experiment produced 3-22 clones. PCR analysis was performed with primer pairs #3, 4, 5 and 6 ( Fig. 4c and Table 3 ) (see Supplementary Fig. 2b ). These results revealed that B16F10 clones derived from 3 clones (CHO HisD #04, 36, 44), but not HisD #21, maintained the correct truncated chromosome.
FISH analysis confirmed that these PCR-positive B16F10 clones containing the targeted chromosome retained the correct targeted chromosome (Fig. 4d and Table 4) .
Thus, at least 3 (6%) of 48 isolated CHO clones were confirmed to have the telomere-associated truncation.
The chromosome modification in mouse A9 cells with CRISPR/Cas9. To induce transgene insertion of neomycin resistant gene and EGFP to a hChr.8 in A9 cell 26 for a model, we designed two sgRNA for CRISPR/ Cas9 expression vectors from a region near centromere of the q arm. The A9 cells containing hChr.8: A9 (hChr.8), were electroporated the two CRISPR/Cas9 vectors and the circular targeting vector. Then, 3 clones (43%) among obtained 7 clones showed the occurrence of HR by PCR analysis (see Supplementary Fig. 3a ). FISH analysis revealed that 2 clones (29%) (A9 KM47 neo #1, 2) of the 7 clones showed the presence of the transgene on the peri-centromeric region of the q arm on hChr.8 (see Supplementary Fig. 3b) . Thus, the chromosome modification techniques with CRISPR/Cas9 was also applicable for A9 human mono-chromosomal library.
Discussion
In this study, 37 blasticidin-resistant CHO clones were obtained from the transgene insertion experiment, and 17 clones showed correct targeting by PCR analysis. Among them, at least, 5 clones showed expected FISH analysis results, and 4 of the 5 clones could show the transfer of the correct targeted chromosome to HT1080 cells. Thus, at least 11% of the isolated clones contained the correct targeted chromosome and were competent to transfer it to the recipient cells.
For the telomere-associated truncation experiment, 48 blasticidin-resistant CHO clones were obtained, and 10 clones showed correct targeting by PCR analysis, and 1 clone showed perfect PCR results. Among the 10 clones, 5 clones showed expected results for FISH analysis, and 3 of these 5 clones were able to transfer the correctly truncated chromosome to B16F10 cells. Thus, 6% of the isolated clones contained the correctly targeted chromosome and could transfer it to the recipient cell.
For transgene insertion in mouse A9 cells, 7 clones were obtained and 3 of the 7 clones showed correct targeting by PCR analysis. Among the 3 clones, 2 clones showed the expected FISH result. Thus, 29% of the isolated clones contained the correct targeted chromosome.
Thus, we have established a CHO-and A9-mediated chromosome engineering technique, including chromosome transfer directly after chromosome modification in CHO-K1 cells containing a human chromosome. FISH analysis is necessary to evaluate if a clone has the correct modified chromosome. To obtain a pure population, single cell cloning with drug selection would improve the purity of each CHO donor clone. Scr-7 is an inhibitor of the non-homologous end-joining DNA repair pathway and can increase the efficiency of homologous recombination 29 . In the telomere-associated truncation experiment, the obtained clones were a mixture of the modified and unmodified cells. Therefore, purification of the clones by FACS or limited dilution may be useful to improve this technique.
MMCT has a possibility to induce chromosomal rearrangement. Most recently, to reduce the possibility with reduction of DNA damage, micronucleation via treatment with TN16 and gliseofulvin, and isolation of microcells with latrunculin B instead of colcemid and cytocharasin B 30 was applied for MMCT as novel methods. The techniques may enable us to obtain the clones without rearrangement of the transferred chromosome.
Thus, the present results advance chromosome engineering for biomedical challenges, such as the production of chromosome aneuploid models and humanized model animals and for identifying genes responsible for genetic disorders 3 .
Materials and Methods
Plasmid construction. Original vectors, I-EGFP-I-Bsd, containing HR arms, the blasticidin resistance gene and EGFP, and pBS-TEL/Dq-HisD, containing 1 kb of artificial telomere, an HR arm and a resistance gene against L-histidinol dihydrochrolid, were previously reported 10 . To construct the I-EGFP-I-Bsd-Fcy; Fur vector for transgene insertion, I-EGFP-I-Bsd was digested with SalI and treated with rapid alkaline phosphatase (Roche, Basel, Switzerland). The Fcy; Fur gene was PCR amplified from pSelect-Zeo-Fcy; Fur (Invitrogen, San Diego, USA) and digested with SalI and XhoI. The fragment was then ligated into the SalI-digested I-EGFP-I-Bsd vector. The following primer pair was used to amplify the Fcy; Fur gene: FcyFur EF1 F: 5′-AAAGTCGACAAACAAACTAGCAAAATAGGCTGTCCC-3′ and FcyFur SV40 R: 5′-AAACTCGAGCCATACCACATTTGTAGAGG-3′. pBS-TEL/Dq HisD-Fcy; Fur was constructed in the following way. pBS-TEL/Dq HisD was digested with Srf1 (TOYOBO, Osaka, Japan) and ligated with a double stranded oligo consisting of: AscI-NotI F: 5′-GGCGCGCCTAAGCGGCCGC-3′ and AscI-NotI R: 5′-GCGGCCGCTTAGGCGCGCC-3′. This plasmid was named pBS-TEL/Dq HisD AN. To construct pBS-TEL/Dq HisD Fcy; Fur, pBS-TEL/Dq HisD AN was digested with NotI and treated with rapid alkaline phosphatase, then ligated with an approximately 2.5kb fragment of pSelect-Zeo-Fcy; Fur, digested with EagI. The 1 kb artificial telomere was fragile in certain E. coli strains; therefore, the pBS-TEL/Dq HisD series was introduced by electroporation and amplified in DH10B (Thermo Fisher, Waltham, USA), an E. Coli strain that could stably maintain the 1 kb artificial telomere. The length of the artificial telomere was confirmed by digestion with HindIII, producing an approximately 1.4 kb band.
CRISPR/Cas9 design. Genomic sequence data of AP000167 and AP001657 loci were obtained from the NCBI database (Accession #. NC_000021 GPC_000001313).
I-EGFP-I-Bsd contained a left arm (approximately 3.4 kb), whose sequence was between 5′-GGGCCCTTAGTGAGAGTTTG-3′ and 5′-ATAGAAGTCCAGGCTGTGGGGCCC-3′ and a right arm (approximately. 2.4 kb) 10 , whose sequence was between 5′-TCTAGAAACTGAATTTATAG-3′ and 5′-GTTACCCAGGATGATCTAGA-3′. The targeted sequences for the CRISPR/Cas9 vector were selected from the sequences between the left and right arm. The telomere truncation vector, pBS-TEL/ Dq HisD, contained a homologous recombination arm (approximately 7kb), whose sequence was between 5′-GGATCCTGAGGCCTGGCAGCGGGCGC-3′ and 5′-TACAATAGAAACCAGAATAA-3′. Therefore, the targeted sequences for CRISPR/Cas9 were downstream of the homologous recombination arm. The CRISPR/Cas9 targeted sequences were designed by the web site, Optimized CRISPR design tool (http://crispr.mit.edu/) 26 . The DNA oligomer in below, was inserted into the BbsI site of pX330-U6-Chimeric_BB-CBh-hSpCas9, which was a gift from Feng Zhang (Massachusetts Institute of Technology) (Addgene plasmid # 42230).
AP000167T1, targeting 5′-GTAAGCCACAAGACAAGTCAGG-3′ was constructed with 5′-CACCGGTAAGCCA CAAGACAAGTC-3′ and 5′-AAACGACTTGTCTTGTGGCTTACC-3′. AP000167T11, targeting 5′-GAAGAAACAT GGCCTAAGGCAGG-3′ was constructed with 5′-CACCGGAAGAAACATGGCCTAAGGC-3′ and 5′-AAACGCC TTAGGCCATGTTTCTTCC-3′.AP001657T5, targeting 5′-GAGAATTGCTTGAACCAGGGAGG-3′ was constructed with 5′-CACCGGAGAATTGCTTGAACCAGGG-3′ and 5′-AAACCCCTGGTTCAAGCAATTCTCC-3′. AP001657T T6, targeting 5′-CTCCTGAGCAGCTGGGACGCAGG-3′ was constructed with 5′-CACCGCTCCTGAGC AGCTGGGACGC-3′ and 5′-AAACGCGTCCCAGCTGCTCAGGAGC-3′.
Evaluation of Cleavage activity for the CRISPR/Cas9 vectors by Cel-I assay. Surveyor ® Mutation
Detection kit (Integrated Device technology, San Jose, USA) was used for evaluation of cleavage activity of the designed CRISPR/Cas9 expression vectors. Each expression vector was transfected into HEK293FT cells (Thermo Fisher), which were seeded at 500,000 cells per well in a 12-well plate. The transfection was performed with Lipofectamine LTX (Thermo Fisher) and 1µg of each plasmid vector, following the manufacturer's instructions. Forty-eight hours after transfection, genomic DNA of the transfected cells was extracted using a Gentra Puregene cell kit (Qiagen, Germantown, USA). The following primer pairs were used for detection of cleavage activity. AP001657T4-7 loci F1:5′-ACAATAGAAACCAGAATAAAAATGG-3′ and AP001657T4-7 loci R1:5′-ATGGTCCATGGGGTTTATCC-3′ were used for evaluation of cleavage activity of AP001657T5 and AP001657T6 CRISPR/Cas9 vectors. AP00167F2:5′-TGTGACCACCATTGACACCTG-3′ and AP00167R2: 5′-CTACAGGCTCCCACCACCAC-3′were used to evaluate the cleavage activity of AP000167T1 CRISPR/ Cas9 vector. AP00167T8-12 loci F1: 5′-TGCCTCTTCTGTGGTGAGTG-3′ and AP00167T8-12 loci R1: 5′-ACTGCATTTGTGTCCCTGTG-3′ were used to evaluate the cleavage activity of AP000167T11 CRISPR/Cas9 vectors. The PCR amplification of the targeted regions was performed with ExTaq (TakaraBio, Kusatsu, Japan). The amplified PCR products were re-annealed by being heated to 95 °C for 10 min, then cooled from 95 °C to 85 °C over 5 sec, from 85 °C to 25 °C over 600 sec, followed by incubation at 25 °C for 1 min, and holding at 4 °C.
Finally, surveyor nuclease treatment was performed under the following conditions. Ten µl of the PCR product, 1 µl SURVEYOR enhancer S, 1 µl SURVEYOR Nuclease S and 0.15 M MgCl 2 were mixed, and incubated at 42 °C for 60 min. Then, the mixture was separated by electrophoresis in a 3% agarose gel and stained with ethidium bromide. Gels were recorded using a gel imaging apparatus (ATTO Technology, Getzvill, USA). The pictures were analysed by image J and a previously reported method PCR. Primer sequences are described below. Primer pair #1 was I-EGFP-I-Bsd long F1: 5′ -CCTGAT TGCCCTGGCCAGAACT TCCATCAC-3′ andI-EGFP-I-Bsd long R1: 5′ -CGCC CTCTCGCACGATTACCATAAAAGGCA-3′, primer pair #2 was Bsd F: 5′-CAACAGCATCCCCATCTCTG-3′ and#21CenG3R: 5′-TTTAGATGCAGGGGCATACTGTGAGCAT-3′, primer pair #3 was q2L:5′-TCATGCCA CAATCAATCTCCCAAGTAGC-3′ and sk23: 5′-GGCCGCTCTAGAACTAGTGGATC-3′, primer pair #4 was Chr. 
FISH.
Metaphase chromosomes were prepared from colcemid-treated cell cultures by hypotonic treatment with 0.075 M KCl and methanol/acetate (3:1) (Wako) fixation. FISH was carried out using human Cot-1 DNA for analysis of CHO and B16F10 or p11-4 32 plasmid containing alpha satellite sequence of Chr.13 and21 for HT1080, labelled with digoxigenin (Roche) and PCR product, amplified from I-EGFP-I-Bsd with primers 5′-GCAACGTGCTGGTTATTGTG-3′ and 5′-AAGGAAAAGTTTAAACTTAGCCCTCCCACACATAAC -3′, and PCR product from pBS-TEL/Dq-HisD with primers 5′-TCGAGGTGAGCCCCACGTTCTG-3′ and 5′-TCGAGGTGAGCCCCACGTTCTG-3′, labelled with biotin (Roche). The DNA probes were labelled with a nick translation kit (Roche). The digoxigenin-labelled DNA probes were detected with an anti-digoxigenin-rhodamine complex (Roche), and the biotin-labelled DNA was detected using avidin-conjugated fluorescein isothiocyanate (FITC; Roche). The chromosomes were counterstained with 4′,6-diamidino-2-phenylindole (DAPI)(Sigma-Aldrich). Metaphase images were captured digitally with a CoolCubeI CCD camera mounted on a fluorescence microscope (Axio Imager, Z2; Carl Zeiss, Promenade, Jena, Germany). Images were processed using the ISIS software provided with the microscope 17 .
Quinacrine hoechst staining. Slides of metaphase spreads were stained with quinacrine mustard (Sigma-Aldrich) and Hoechst 33258 (Sigma-Aldrich) for observation of the chromosome size and banding pattern. Metaphase images were captured digitally with a CoolCubeI CCD camera mounted on a fluorescence microscope were processed using the ISIS software provided with the microscope.
MMCT. Donor CHO cells were expanded in T-25 flasks (Thermo Fisher), in Ham's-F12medium containing 20% FBS and 0.1 µg/mL colcemid (Thermo Fisher) and incubated at 37 °C for 48h to induce micronucleation. The culture medium was then refreshed, and cells were incubated for another 24 h. The T-25 flask containing CHO cells with micronuclei was filled with DMEM containing 10 µg/mL cytochalasin B (Sigma-Aldrich) and centrifuged for 1h using an Avanti HP-26XP, JLA-10,500 rotor (Beckman Coulter Life Sciences, Indianapolis, USA) at 11,900 × g to form microcells. The pellet including microcells was collected and filtered through 8-, 5-, and 3-µm pore-size filters to purify microcells. Microcell pellets were collected by centrifugation at 760 × g with a table-top centrifuge (Kubota Corporation, Tokyo, Japan). To introduce the chromosome fragments to the HT1080 or B16F10 recipient cells, 2 × 10 6 cells were prepared in a 6-cm dish (Corning, Corning, USA). The microcell pellets were suspended in 2mL DMEM containing 0.05 mg/mL phytohemagglutinin P (Sigma-Aldrich). This suspension was added to the recipient cells and the dish was incubated for 20 min and then treated with PEG1000 (Wako) containing 10% DMSO to fuse microcells and recipient cells. These fused cells were incubated for 24 h at 37 °C in DMEM containing 10% FBS and 12 µg/mL of blasticidin S for HT1080 cells and 7 mM L-histidinol dihydrochrolid for B16F10 cells 33 .
